Level 1 - Absolute Beginner

Cancer is a serious illness where cells in the body grow in the wrong way. One very dangerous type is called pancreatic cancer. It is hard to treat and many people do not survive it.

Scientists found a new medicine called daraxonrasib. It is a tablet that people take every day. It was made to fight a part of cancer cells called KRAS.

In a big study, doctors gave the new medicine to people with pancreatic cancer. People who took it lived for about 13 months on average. People who took regular medicine lived for about 7 months.

This is a very big discovery. Scientists published the results in a famous medical journal in May 2026. Doctors are very excited because this could help many patients.

cancer

a disease in which some cells in the body grow and divide in an uncontrolled way, harming healthy tissue

pancreatic cancer

a type of cancer that starts in the pancreas, a large gland behind the stomach that helps with digestion and blood sugar control

medicine

a substance taken by a person to treat or prevent illness

patient

a person who is receiving medical treatment from a doctor

clinical trial

a scientific study that tests a new medicine or treatment in people to see if it is safe and effective

journal

a publication in which scientists and doctors share the results of their research

survival

the act of continuing to live, especially after a serious illness or dangerous event

treatment

the process of using medicine or other methods to cure or improve a medical condition

Level 2 - Elementary

Pancreatic cancer is one of the deadliest cancers in the world. Most patients are diagnosed when the cancer has already spread, and the average survival time is usually less than a year with current treatments. Scientists have been searching for better treatments for decades.

A company called Revolution Medicines has developed a drug called daraxonrasib. In a large Phase 3 clinical trial called RASolute 302, which included 500 patients from North America, Europe, and Asia, the drug nearly doubled how long patients lived compared to standard chemotherapy. Patients on daraxonrasib survived an average of 13.2 months, compared to 6.7 months for those on chemotherapy.

Daraxonrasib targets a protein called KRAS, which doctors have wanted to block for more than 40 years. KRAS sends signals that tell cancer cells to grow and multiply. The problem is that KRAS was so difficult to attack with medicines that scientists once called it 'undruggable.' Daraxonrasib solves this by attaching to a helper molecule called cyclophilin A, which then connects to and blocks the active KRAS protein.

The results were published on May 31, 2026 in the New England Journal of Medicine, one of the most important medical journals in the world. The drug reduced the risk of death by 60 percent compared to chemotherapy. Scientists and doctors described the results as a genuine breakthrough for a disease that has seen very little progress for many years.

Phase 3 clinical trial

the final and largest stage of testing a new medicine in a large group of patients before it can be approved by regulators

chemotherapy

a treatment for cancer that uses powerful drugs to kill or slow the growth of cancer cells throughout the body

KRAS protein

a protein in cells that, when mutated, acts like a permanently stuck accelerator, sending continuous signals telling cancer cells to grow and divide

undruggable

a target in the body that scientists believed for many years could not be blocked by a medicine because of its shape or location

cyclophilin A

a protein found in cells that helps fold other proteins into their correct 3D shape; daraxonrasib binds to it to reach and block KRAS

median overall survival

the time at which half of the patients in a clinical trial are still alive; used to compare the effectiveness of treatments

metastatic

describing cancer that has spread from its original location to other parts of the body

breakthrough

a sudden important discovery or development that removes a barrier to progress

Level 3 - Intermediate

Revolution Medicines announced on May 31, 2026, that its RAS(ON) inhibitor daraxonrasib met its primary endpoint in the 500-patient Phase 3 RASolute 302 trial, nearly doubling median overall survival in previously treated metastatic pancreatic ductal adenocarcinoma. Patients receiving daraxonrasib survived a median of 13.2 months, compared with 6.7 months for those on physician's choice chemotherapy - a 60 percent reduction in the risk of death. The results were simultaneously published in the New England Journal of Medicine.

KRAS mutations drive approximately 90 percent of pancreatic ductal adenocarcinomas and have been considered undruggable since the protein was first described in 1982. Earlier attempts to develop direct KRAS inhibitors failed because the protein's smooth surface provided no accessible binding site for small-molecule drugs. Daraxonrasib circumvents this problem through an indirect mechanism: it binds to cyclophilin A, a ubiquitous chaperone protein responsible for folding other proteins into their functional 3D shapes. The resulting daraxonrasib-cyclophilin A complex then attaches to the active KRAS protein, switching it off and blocking the downstream signalling cascade that drives uncontrolled cell proliferation.

The trial enrolled 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma who had an Eastern Cooperative Oncology Group performance status of 0 or 1. Participants were randomly assigned to either daraxonrasib (248 patients) or chemotherapy (252 patients). Crucially, eligibility required an ECOG performance status indicating the patient was relatively fit, which means the results cannot be directly extrapolated to the sickest patients who are often unable to tolerate aggressive treatment.

Dana-Farber Cancer Institute, which co-led the trial, described the results as representing an unprecedented overall survival benefit in this disease setting. Oncologists noted, however, that the 13.2-month median, while historically impressive for second-line metastatic pancreatic cancer, still reflects a disease with very poor long-term prognosis. Revolution Medicines has indicated it will seek FDA approval under priority review and is already designing a first-line combination trial pairing daraxonrasib with the standard FOLFIRINOX regimen.

RAS(ON) inhibitor

a drug that blocks the 'always-on' form of a RAS protein such as KRAS, which in its mutated state constantly signals cells to grow

metastatic pancreatic ductal adenocarcinoma

the most common type of pancreatic cancer that has spread beyond the pancreas to other organs, making it very difficult to treat

primary endpoint

the main outcome that a clinical trial is designed to measure, such as overall survival or tumour shrinkage, used to judge whether the treatment works

chaperone protein

a molecule that helps other proteins fold into their correct three-dimensional shape, which is required for them to function properly

Level 4 - Advanced

Revolution Medicines reported top-line results from the Phase 3 RASolute 302 trial (NCT05727813) on May 31, 2026, demonstrating that daraxonrasib, its orally bioavailable RAS(ON) multi-selective inhibitor, extended median overall survival from 6.7 months to 13.2 months versus physician's choice chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC), representing a hazard ratio of approximately 0.40 (95 percent CI 0.31-0.52) and a 60 percent reduction in the risk of death at the data cut-off. Pre-specified secondary endpoints included a statistically significant improvement in progression-free survival and objective response rate. The results were published simultaneously in the New England Journal of Medicine.

The mechanistic basis for daraxonrasib's activity distinguishes it from the first-generation allele-specific KRAS-G12C inhibitors (sotorasib, adagrasib) that achieved regulatory approval between 2021 and 2023 but were limited to the G12C substitution found in only 1-2 percent of PDAC tumours. KRAS-G12D, present in approximately 42 percent of mPDAC, and KRAS-G12V, present in approximately 34 percent, have resisted direct targeting because both wild-type and G12X-mutant KRAS adopt a GTP-bound 'ON' conformation that lacks the cryptic switch-II pocket exploitable by G12C-specific covalent inhibitors. Daraxonrasib sidesteps this constraint through a cyclophilin A-mediated ternary complex mechanism: the compound bridges cyclophilin A's peptidyl-prolyl isomerase active site to the switch I-II interface of GTP-bound KRAS, inducing an allosteric conformational shift that uncouples KRAS from RAF and PI3K effectors.

The trial enrolled 500 patients with ECOG PS 0-1 across 127 sites in North America, Europe, Asia-Pacific, and Israel. Stratification factors included prior lines of therapy, geographic region, and KRAS allele (G12D versus non-G12D). Subgroup analyses showed consistent benefit across KRAS subtypes, with non-statistically-significant trends toward larger absolute OS gain in the G12D cohort (mOS 14.8 versus 6.4 months, HR 0.37) relative to G12V (mOS 12.1 versus 7.1 months, HR 0.44). The most common grade 3 or higher adverse events were nausea (8.1 percent), fatigue (7.3 percent), and alanine aminotransferase elevation (5.6 percent) - a substantially more manageable toxicity profile than standard FOLFIRINOX.

The regulatory pathway is straightforward: the NDA submission under Breakthrough Therapy Designation is expected in Q3 2026, with FDA priority review and a potential PDUFA date in Q1 2027. The pivotal question for commercial uptake will be whether daraxonrasib achieves reimbursement at a price consistent with an ICER (incremental cost-effectiveness ratio) that payers consider acceptable for an additional approximately 6.5 months of life in second-line mPDAC - a disease area where prior economic modelling using quality-adjusted life-years has produced heterogeneous conclusions across European HTA bodies and the US Institute for Clinical and Economic Review.

hazard ratio (HR)